Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers: Cell-Free Nucleic Acids, Proteins and Rare Circulating Cells

Sehyun Shin's Biography

Sehyun Shin, Professor & Director, Nano-Biofluignostic Engineering Research Center, Korea University and Anam/Guro Hospital of Korea University

Professor Shin is currently professor of School of Mechanical Engineering and College of Medicine at Korea University and the director of Nano-Biofluignostic Engineering Research Center. He also has served as the Editor of the Journal of Mechanical Science and Technology (JMST). His research interests include the liquid biopsy for cancer and infectious viruses and the development of microfluidic technologies for disease detection, diagnosis and therapy. He has authored more than 150 peer-reviewed papers and delivered more than 130 invited talks and plenary lectures. He is as the president of International Society of Clinical Hemorheology as well as president of Biomedical Engineering Society of Cardiovascular Diseases. Prof. Shin co-founded three startups which are commercializing technologies developed in his lab. He has garnered many research awards and honors including Presidential citation of Science and Technology Merit by the Korean government, award for the Scientist of the month by NRF, the Academic award of KSME, the Nam-Heon Academic Award for Thermal engineering, Fellow of the ISCH, Fellow of KSME and Fellow of KSOR. Finally, Prof. Shin currently heads a group of 15 researchers.

Sehyun Shin Image

Closed Microfluidic PCR-based Surface Plasmon Resonance Biosensor for Multiple Detection of Circulating Tumor DNAs

Monday, 20 March 2017 at 17:00

Add to Calendar ▼2017-03-20 17:00:002017-03-20 18:00:00Europe/LondonClosed Microfluidic PCR-based Surface Plasmon Resonance Biosensor for Multiple Detection of Circulating Tumor

Circulating tumor DNA (ctDNA) has been demonstrated as the most promising biomarker for non-invasive assessment of cancer as well as the most accurate predictor of cancer treatment responses. However, there are several hundreds of tumor DNAs even for one organ cancer (i.e., Lung cancer) and thus multiplexing is highly required for cancer detection from blood. The conventional techniques have been faced critical limits including multiplexing and cost and thus innovative technologies are highly required. Here, we present a highly precise and selective assay for detecting epidermal growth factor receptor (EGFR) mutations in plasma (or liquid biopsy) using DNA-DNA hybridization and Au nanoparticle probe with a lab-made surface plasmon resonance (SPR) sensometry. Targeted DNAs are amplified in a closed-loop microfluidic PCR module consisting of three different temperature regions. We prepared wild type EGFR, EGFR mutants including point mutation and deletion. Linker DNAs coated on a sensor surface of SPR captured different DNA types. Due to characteristics of SPRi, the whole assay process was monitored in real-time and completed within an hour. This study as a proof of concept can be further expanded into high degree of multiplexing detection of major and known ctDNAs, which could provide a solution for clinical unmet needs in cancer treatment and early detection.

Add to Calendar ▼2017-03-20 00:00:002017-03-21 00:00:00Europe/LondonCirculating Biomarkers: Cell-Free Nucleic Acids, Proteins and Rare Circulating